Jenna N Regan1, Trupti Trivedi1, Theresa A Guise1, David L Waning2. 1. Indiana University School of Medicine, Indianapolis, IN, 46202, USA. 2. The Pennsylvania State University College of Medicine, 500 University Drive, H166, Rm C4710E, Hershey, PA, 17033, USA. dwaning@psu.edu.
Abstract
PURPOSE OF REVIEW: The role of bone-derived factors in regulation of skeletal muscle function is an important emerging aspect of research into bone-muscle crosstalk. Implications for this area of research are far reaching and include understanding skeletal muscle weakness in cancer, osteoporosis, cachexia, rare diseases of bone, and aging. RECENT FINDINGS: Recent research shows that bone-derived factors can lead to changes in the skeletal muscle. These changes can either be anabolic or catabolic, and we focus this review on the role of TGFβ in driving oxidative stress and skeletal muscle weakness in the setting of osteolytic cancer in the bone. The bone is a preferred site for breast cancer metastasis and leads to pathological bone loss. Osteolytic cancer in the bone leads to release of TGFβ from the bone via osteoclast-mediated bone destruction. Our appreciation of crosstalk between the muscle and bone has recently expanded beyond mechanical force-driven events to encompass a variety of signaling factors originating in one tissue and communicating to the other. This review summarizes some previously known mediators of bone-to-muscle signaling and also recent work identifying a new role for bone-derived TGFβ as a cause of skeletal muscle weakness in the setting of osteolytic cancer in the bone. Multiple points of potential therapeutic intervention are discussed.
PURPOSE OF REVIEW: The role of bone-derived factors in regulation of skeletal muscle function is an important emerging aspect of research into bone-muscle crosstalk. Implications for this area of research are far reaching and include understanding skeletal muscle weakness in cancer, osteoporosis, cachexia, rare diseases of bone, and aging. RECENT FINDINGS: Recent research shows that bone-derived factors can lead to changes in the skeletal muscle. These changes can either be anabolic or catabolic, and we focus this review on the role of TGFβ in driving oxidative stress and skeletal muscle weakness in the setting of osteolytic cancer in the bone. The bone is a preferred site for breast cancer metastasis and leads to pathological bone loss. Osteolytic cancer in the bone leads to release of TGFβ from the bone via osteoclast-mediated bone destruction. Our appreciation of crosstalk between the muscle and bone has recently expanded beyond mechanical force-driven events to encompass a variety of signaling factors originating in one tissue and communicating to the other. This review summarizes some previously known mediators of bone-to-muscle signaling and also recent work identifying a new role for bone-derived TGFβ as a cause of skeletal muscle weakness in the setting of osteolytic cancer in the bone. Multiple points of potential therapeutic intervention are discussed.
Authors: Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué Journal: Proc Natl Acad Sci U S A Date: 2005-09-19 Impact factor: 11.205
Authors: Xin Lu; Euphemia Mu; Yong Wei; Sabine Riethdorf; Qifeng Yang; Min Yuan; Jun Yan; Yuling Hua; Benjamin J Tiede; Xuemin Lu; Bruce G Haffty; Klaus Pantel; Joan Massagué; Yibin Kang Journal: Cancer Cell Date: 2011-12-01 Impact factor: 31.743
Authors: Daniel C Andersson; Matthew J Betzenhauser; Steven Reiken; Albano C Meli; Alisa Umanskaya; Wenjun Xie; Takayuki Shiomi; Ran Zalk; Alain Lacampagne; Andrew R Marks Journal: Cell Metab Date: 2011-08-03 Impact factor: 27.287
Authors: Justin L Chen; Kelly L Walton; Catherine E Winbanks; Kate T Murphy; Rachel E Thomson; Yogeshwar Makanji; Hongwei Qian; Gordon S Lynch; Craig A Harrison; Paul Gregorevic Journal: FASEB J Date: 2013-12-30 Impact factor: 5.191
Authors: Lauren K Dunn; Khalid S Mohammad; Pierrick G J Fournier; C Ryan McKenna; Holly W Davis; Maria Niewolna; Xiang Hong Peng; John M Chirgwin; Theresa A Guise Journal: PLoS One Date: 2009-09-03 Impact factor: 3.240
Authors: Benjamin Osipov; Manali P Paralkar; Armaun J Emami; Hailey C Cunningham; Priscilla M Tjandra; Suraj Pathak; Henning T Langer; Keith Baar; Blaine A Christiansen Journal: J Orthop Res Date: 2021-06-13 Impact factor: 3.494
Authors: Alyson L Essex; Fabrizio Pin; Joshua R Huot; Lynda F Bonewald; Lilian I Plotkin; Andrea Bonetto Journal: Front Endocrinol (Lausanne) Date: 2019-11-19 Impact factor: 5.555
Authors: Alyson L Essex; Joshua R Huot; Padmini Deosthale; Alison Wagner; Jorge Figueras; Azaria Davis; John Damrath; Fabrizio Pin; Joseph Wallace; Andrea Bonetto; Lilian I Plotkin Journal: J Bone Miner Res Date: 2022-06-07 Impact factor: 6.390
Authors: N H Hart; S Nimphius; T Rantalainen; A Ireland; A Siafarikas; R U Newton Journal: J Musculoskelet Neuronal Interact Date: 2017-09-01 Impact factor: 2.041